| Title |
The impact of metformin on survival in diabetic endometrial cancer patients: a retrospective population-based analysis / |
| Authors |
Drevinskaitė, Mingailė ; Kačėnienė, Augustė ; Linkevičiūtė-Ulinskienė, Donata ; Smailytė, Giedrė |
| DOI |
10.1007/s40200-023-01358-3 |
| Full Text |
|
| Is Part of |
Journal of diabetes and metabolic disorders.. Cham : Springer Science and Business Media Deutschland GmbH. 2024, vol. 23, iss. 1, p. 841-847.. eISSN 2251-6581 |
| Keywords [eng] |
cancer-specific survival ; endometrial cancer ; metformin ; overall survival ; type 2 diabetes mellitus |
| Abstract [eng] |
Purpose: The aim of our study was to assess overall survival and cancer-specific survival in endometrial cancer patients with type 2 diabetes mellitus (T2DM) using metformin. Methods: Patients with endometrial cancer and T2DM during 2000–2012 period were identified from the Lithuanian Cancer Registry and the National Health Insurance Fund database. Cancer-specific and overall survival were primary outcomes. Results: In our study we included 6287 women with endometrial cancer out of whom 664 were diagnosed with T2DM (598 metformin users and 66 never users). During follow-up (mean follow-up time was 8.97 years), no differences in risk of endometrial cancer specific mortality was observed in diabetic patients treated with metformin (Hazard Ratio (HR) 0.87, 95% Confidence Interval (CI) 0.70–1.07). Overall mortality in the diabetic metformin ever users’ group was significantly higher compared with the non-diabetic endometrial cancer women (HR 1.17, 95% CI 1.03–1.32) and in the group of metformin never users with T2DM (HR 1.42, 95% CI 1.07–1.87). Conclusion: Our study results suggest no beneficial impact on overall and cancer-specific survival in endometrial cancer patients who were treated with metformin as part of their diabetes treatment. |
| Published |
Cham : Springer Science and Business Media Deutschland GmbH |
| Type |
Journal article |
| Language |
English |
| Publication date |
2024 |
| CC license |
|
